New combo therapy for breast cancer aims to improve outcomes without extra harm
Disease control
Not yet recruiting
This early-stage study tests whether adding a targeted drug (CDK4/6 inhibitor) to standard radiation after surgery is safe and tolerable for women with a common type of high-risk breast cancer (HR+/HER2-). About 30 participants will receive the combination, and researchers will m…
Phase: EARLY_PHASE1 • Sponsor: Guizhou Provincial People's Hospital • Aim: Disease control
Last updated Apr 29, 2026 15:01 UTC